News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Galleon Pharmaceuticals, Inc. Demonstrates Successful Clinical Proof-of-Concept for Lead Product From Sleep Apnea Drug-Discovery Platform


4/11/2013 12:10:44 PM

HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals announced today a clinically significant outcome in a clinical proof-of-concept study evaluating the ability of its lead investigational drug, GAL-021, to successfully regulate respiratory drive, a key requirement to prevent respiratory complications in high-risk surgical patients. This is the first time a drug has been shown to regulate and protect respiratory drive from drug-induced respiratory depression. In this study, intravenous GAL-021 was able to reverse respiratory depression under challenging conditions including high doses of opioids and elevated carbon-dioxide levels, which can be particularly problematic for post-surgical and sleep apnea patients. The Company is actively seeking funding to advance this promising candidate into a broad Phase II program.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES